Abstract
Gene therapy, in which oligomeric genetic material is carried into cells by nano-sized gene delivery vehicles to interfere with gene expression, represents a promising approach for preventive therapy against HIV/AIDS pandemic. Herein, we evaluate the usefulness of a phosphorus-containing dendrimer G4(NH+Et2Cl-)96 as a delivery agent of ODNs and siRNAs. G4(NH+Et2Cl-)96 formed stable complexes with ODNs or siRNAs and exhibited very low cytotoxicity in Sup T1 cells or PBMC. Functional validation was performed by using specific siRNA against HIV-1 Nef, siNEF to interfere in HIV-1 replication. G4(NH+Et2Cl-)96/siNEF dendriplex showed a high efficiency in Nef silencing. Furthermore, in vitro treatment of HIV-infected PBMC with G4(NH+Et2Cl-)96/siNEF dendriplex significantly reduced the viral replication. Our results prove the usefulness of phosphorus-containing dendrimers to deliver and transfect siRNA into CD4-T cells as a potential alternative therapy in the HIV-1 infection.
Keywords: Nanomedicine, phosphorus dendrimer, HIV, oligodeoxynucleotides, siRNA and gene therapy
Current Medicinal Chemistry
Title:Validation of a Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1
Volume: 19 Issue: 29
Author(s): V. Briz, M.J. Serramia, R. Madrid, A. Hameau, Anne-Marie Caminade, J.P. Majoral and M.A. Munoz-Fernandez
Affiliation:
Keywords: Nanomedicine, phosphorus dendrimer, HIV, oligodeoxynucleotides, siRNA and gene therapy
Abstract: Gene therapy, in which oligomeric genetic material is carried into cells by nano-sized gene delivery vehicles to interfere with gene expression, represents a promising approach for preventive therapy against HIV/AIDS pandemic. Herein, we evaluate the usefulness of a phosphorus-containing dendrimer G4(NH+Et2Cl-)96 as a delivery agent of ODNs and siRNAs. G4(NH+Et2Cl-)96 formed stable complexes with ODNs or siRNAs and exhibited very low cytotoxicity in Sup T1 cells or PBMC. Functional validation was performed by using specific siRNA against HIV-1 Nef, siNEF to interfere in HIV-1 replication. G4(NH+Et2Cl-)96/siNEF dendriplex showed a high efficiency in Nef silencing. Furthermore, in vitro treatment of HIV-infected PBMC with G4(NH+Et2Cl-)96/siNEF dendriplex significantly reduced the viral replication. Our results prove the usefulness of phosphorus-containing dendrimers to deliver and transfect siRNA into CD4-T cells as a potential alternative therapy in the HIV-1 infection.
Export Options
About this article
Cite this article as:
Briz V., Serramia M.J., Madrid R., Hameau A., Caminade Anne-Marie, Majoral J.P. and Munoz-Fernandez M.A., Validation of a Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1, Current Medicinal Chemistry 2012; 19 (29) . https://dx.doi.org/10.2174/0929867311209025044
DOI https://dx.doi.org/10.2174/0929867311209025044 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Articular Bleeding in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms Involved in BACE Upregulation Associated to Stress
Current Alzheimer Research Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Editorial [Hot Topic:Drug Targets in Ageing and Age-Associated Diseases (Executive Editors: C. Caruso and E. Jirillo)]
Current Pharmaceutical Design Optical Coherence Tomography: A Journey from Clinical Research to Daily Interventional Practice
Recent Patents on Medical Imaging 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates
Current Computer-Aided Drug Design The Development and In Vitro Evaluation of Sustained Release Tablet Formulations of Benzydamine Hydrochloride and its Determination
Combinatorial Chemistry & High Throughput Screening The Role of Osteopontin in Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
Inflammation & Allergy - Drug Targets (Discontinued) In silico Approaches for the Identification of Optimal Culture Condition for Tissue Engineered Bone Substitutes
Current Analytical Chemistry The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Gastric Cytoprotection Beyond Prostaglandins: Cellular and Molecular Mechanisms of Gastroprotective and Ulcer Healing Actions of Antacids
Current Pharmaceutical Design Editorial [ Hot Topic:Endocannabinoid-Binding Receptors: Old Friends and New Comers (Guest Editor: Mauro Maccarrone)]
Current Medicinal Chemistry Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Inhibitors and Modulators of β- and γ-Secretase
Current Topics in Medicinal Chemistry DNA and RNA Aptamers as Modulators of Protein Function
Medicinal Chemistry